Janus Henderson Form 4 Change in insider ownership

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

JANUS HENDERSON GROUP PLC

(Last)

(First)

(Middle)

201 BISHOPGATE

(Street)

LONDON

EC2M 3AE

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARCA biopharma, Inc. [ ABIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/03/2024		P		166,042	A	$3.5507	1,648,577	I	By Fund⁽¹⁾
Common Stock	07/05/2024		P		23,326	A	$3.4303	1,671,903	I	By Fund⁽¹⁾
Common Stock	07/05/2024		P		5,000	A	$3.41	1,676,903	I	By Fund⁽¹⁾
Common Stock	07/08/2024		P		29,892	A	$3.4114	1,706,795	I	By Fund⁽¹⁾
Common Stock	07/08/2024		P		17,600	A	$3.535	1,724,395	I	By Fund⁽¹⁾
Common Stock	07/09/2024		P		16,917	A	$3.4339	1,741,312	I	By Fund⁽¹⁾
Common Stock	07/10/2024		P		33,500	A	$3.4647	1,774,812	I	By Fund⁽¹⁾
Common Stock	07/10/2024		P		21,963	A	$3.4632	1,796,775	I	By Fund⁽¹⁾
Common Stock	07/11/2024		P		94,537	A	$3.4516	1,891,312	I	By Fund⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

JANUS HENDERSON GROUP PLC

(Last)

(First)

(Middle)

201 BISHOPGATE

(Street)

LONDON

EC2M 3AE

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Janus Henderson Biotech Innovation Master Fund Ltd

(Last)

(First)

(Middle)

201 BISHOPGATE

(Street)

LONDON

EC2M 3AE

(City)

(State)

(Zip)

Explanation of Responses:

1. The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

	/s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary	07/12/2024
	/s/ Janus Henderson Biotech Innovation Master Fund Ltd., By: Janus Henderson Investors US LLC, By: Peter Falconer, Assistant Secretary	07/12/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Janus Henderson (JHG) Form 4Change in insider ownership